JPMorgan Chase & Co. set a €95.00 ($113.10) target price on Merck KGaA (FRA:MRK) in a research note released on Friday, December 29th. The brokerage currently has a neutral rating on the healthcare company’s stock.
A number of other research analysts have also commented on the company. UBS Group set a €120.00 ($142.86) target price on Merck KGaA and gave the company a buy rating in a research note on Monday, October 23rd. Berenberg Bank set a €116.00 ($138.10) target price on Merck KGaA and gave the company a buy rating in a research note on Thursday, November 23rd. equinet set a €112.00 ($133.33) target price on Merck KGaA and gave the company a buy rating in a research note on Thursday, August 31st. Societe Generale set a €103.00 ($122.62) target price on Merck KGaA and gave the company a neutral rating in a research note on Tuesday, September 5th. Finally, Bank of America set a €95.00 ($113.10) target price on Merck KGaA and gave the company a neutral rating in a research note on Wednesday, December 6th. Twelve investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The company presently has an average rating of Hold and an average price target of €107.57 ($128.06).
Shares of Merck KGaA (MRK) traded down €0.46 ($0.55) during midday trading on Friday, reaching €91.26 ($108.64). 453,221 shares of the company were exchanged. The stock has a market cap of $11,770.00 and a price-to-earnings ratio of 21.37. Merck KGaA has a 52 week low of €87.33 ($103.96) and a 52 week high of €115.00 ($136.90).
WARNING: This report was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://ledgergazette.com/2018/01/13/merck-kgaa-mrk-given-a-95-00-price-target-at-jpmorgan-chase-co.html.
Merck KGaA Company Profile
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.